Sucrose stearate-based proniosome-derived niosomes for the nebulisable delivery of cromolyn sodium

被引:87
作者
Abd-Elbary, A. [1 ]
El-laithy, H. M. [1 ]
Tadros, M. I. [1 ]
机构
[1] Cairo Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Cairo, Egypt
关键词
proniosomes; cromolyn sodium; nebulisation; sucrose stearate; physical stability;
D O I
10.1016/j.ijpharm.2008.01.056
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A Novel approach was developed for the preparation of controlled release proniosome-derived niosomes, using sucrose stearates as non-ionic biocompatible surfactants for the nebulisable delivery of cromolyn sodium. Conventional niosomes were prepared by a reverse phase evaporation method followed by the preparation of proniosomes by spraying the optimized surfactant-lipid mixture of sucrose stearate, cholesterol and stearylamine in 7:3:0.3 molar ratio onto the surface of spray dried lactose powder. Proniosome-derived niosomes were obtained by hydrating proniosomes with 0.9% saline at 50 degrees C and mixing for approximately 2min. All vesicles were evaluated for their particle size, morphological characteristics, entrapment efficiency, in vitro drug release, nebulisation efficiency and physical stability at 2-8 degrees C. In addition, coating carrier surface with the surfactant-lipid mixture, during preparation of proniosomes, resulted in smaller, free flowing, homogenous and smooth vesicles with high drug entrapment efficiency. Compared to a standard drug solution, a successful retardation of the drug release rate was achieved with the proniosome-derived niosomes, where the t(50%) value of the release profile was 18.1 h compared to 1.8 h. Moreover, high nebulisation efficiency percentage and good physical stability were also achieved. The results are very encouraging and offer an alternative approach to minimize the problems associated with conventional niosomes like degradation, sedimentation, aggregation and fusion. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:189 / 198
页数:10
相关论文
共 43 条
[1]  
ABDELBARY A, 2007, ARCH PHARM RES, V30, P785
[2]   Proniosomes as a drug carrier for transdermal delivery of ketorolac [J].
Alsarra, IA ;
Bosela, AA ;
Ahmed, SM ;
Mahrous, GM .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2005, 59 (03) :485-490
[3]  
Betageri G., 1994, PHARM ENG, V14, P76
[4]   SEM imaging predicts quality of niosomes from maltodextrin-based proniosomes [J].
Blazek-Welsh, AI ;
Rhodes, DG .
PHARMACEUTICAL RESEARCH, 2001, 18 (05) :656-661
[5]   Maltodextrin-based proniosomes [J].
Blazek-Welsh, AI ;
Rhodes, DG .
AAPS PHARMSCI, 2001, 3 (01) :art. no.-1
[6]   Characterization of surfactant effect on aggregates in model aerosol propellent suspensions [J].
Bower, C ;
Washington, C ;
Purewal, TS .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1996, 48 (04) :337-341
[7]   An investigation of some of the factors influencing the jet nebulisation of liposomes [J].
Bridges, PA ;
Taylor, KMG .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 204 (1-2) :69-79
[8]  
BRIDGES PA, 1995, P INT S CONTR REL BI, V22, P2021
[9]  
*BRIT PHARM, 2004, AER ASS FIN PART FIN, pA204
[10]   Effect of particle size, air flow and inhaler device on the aerosolisation of disodium cromoglycate powders [J].
Chew, NYK ;
Bagster, DF ;
Chan, HK .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 206 (1-2) :75-83